Buy Rozerem- Kill Sleepless Nights
Nearly a third of the U.S. population experiences disrupted sleep, which can include problems falling asleep, inability to stay asleep, and failure to feel restored by sleep. Sleep in 10 percent of the population is so dysfunctional that it impairs daytime performance and therefore qualifies as insomnia. For most of these people, insomnia occurs night after night for months or years.
Insomnia was traditionally considered a condition that arises from a separate health problem. Depression or chronic pain, for example, can disrupt sleep. What's more, some medications, such as the drugs prescribed for attention-deficit hyperactivity disorder, can get in the way of a good night's sleep.
Disease, distress, and drugs contribute to sleep difficulties, says sleep-disorders researches. But insomnia usually doesn't disappear when those conditions improve.
Takeda Global Research & Development Center Inc. has received an approval from the U.S. Food and Drug Administration (FDA) for ROZEREM (ramelteon), 8 mg tablets for the treatment of insomnia. ROZEREM is the first and only prescription sleep medication not designated as a controlled substance by the U.S. Drug Enforcement Administration (DEA). Takeda Pharmaceuticals North America, Inc. will market ROZEREM in the US market.
ROZEREM has a unique therapeutic mechanism of action as compared to existing insomnia treatments because it selectively targets two receptors in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's "master clock" because it regulates 24-hour or "circadian" rhythms, including the sleep-wake cycle.
ROZEREM, the insomnia drug has been shown to decrease the time to sleep onset in controlled clinical trials with the wide range of patients including older adults, and also to carry minimal risks of rebound insomnia and dependency.
You can safely buy Rozerem (ramelteon), which has been approved by the Food and Drug Administration along with the hypnotic drugs Lunesta (eszopiclone) and a new, slow-release formulation of zolpidem called Ambien CR. At least one other hypnotic compound, indiplon, could appear in pharmacies next year. A few novel anti-insomnia drugs are currently being tested.
About the Author
Saira Simmons is a well known author who has long been writing articles related to health & fitness. Her articles are well known across the web for being quite informative and according to the changing trend in the pharmacy industry. saira.simmons@gmail.com www.presriptionsfirst.com
Tell others about
this page:
Comments? Questions? Email Here